干细胞移植治疗扩张型心肌病疗效与安全性的Meta分析

朱琳; 明黎; 童可; 李秋姝; 余更生

doi:10.13201/j.issn.1001-1439.2021.05.013

干细胞移植治疗扩张型心肌病疗效与安全性的Meta分析

- 重庆医科大学附属儿童医院心内科儿童发育疾病研究教育部重点实验室国家儿童健康与疾病临床医学研究中心儿童发育重大疾病国家国际科技合作基地儿科学重庆市重点实验室(重庆,400014)

详细信息

通讯作者: 余更生,E-mail:yugengsheng@163.com

中图分类号: R542.2

收稿日期: 2020-12-04

A Meta-analysis of the efficacy and safety of stem cell transplantation in patients with dilated cardiomyopathy

- Department of Cardiology, Children's Hospital of Chongqing Medical University;Ministry of Education Key Laboratory of Child Developmental Disorder;National Clinical Research Center for Child Health and Disorders;China International Science and Technology Cooperation Base of Child Development and Critical Disorders;Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China

More Information

Corresponding author: YU Gengsheng, E-mail: yugengsheng@163.com

Received Date: 04 December 2020

摘要

摘要: 目的:系统评价干细胞移植治疗扩张型心肌病的疗效与安全性。方法:对PubMed、Embase、Cochrane Library、Medline、Web of Science及知网、维普、万方、CBM于2020年10月1日前发表的随机对照试验进行系统检索。采用RevMan5.3及STATA15进行Meta分析。结局指标包括病死率及不良事件发生率、左心室射血分数(LVEF)、左心室舒张末期容积(LVEDCs)、左心室收缩末期容积(LVESCs)、六分钟步行距离(6MWD)、氨基末端脑钠尿肽前体(NT-proBNP)。结果:最终纳入9项随机对照试验,共包括607例患者。Meta分析结果表明,干细胞移植不会增加病死率(RR=0.72,95%CI:0.52~1.01,P=0.196)及不良事件发生率(RR=1.25,95%CI:0.68~2.27,P=0.617),并可提高LVEF(WMD=5.02,95%CI:3.32~6.73,P=0.005),降低LVEDCs(SMD=-0.82,95%CI:-1.42~-0.22,P=0)及NT-proBNP(WMD=-1534.00,95%CI:-2410.06~-657.95,P=0);但对LVESCs(SMD=0.12,95%CI:-0.78~1.01,P=0);和6MWD(WMD=51.39,95%CI:-11.65~114.43,P=0)无影响。结论:干细胞移植治疗扩张型心脏病不会增加病死率及不良事件发生率,对提高LVEF、降低LVEDCs及NT-proBNP有一定疗效,但对降低LVESCs和提高6MWD影响不大,未来还需更多大型随机对照试验来进一步明确干细胞治疗对扩张型心肌病患者的影响。
- 干细胞移植 /
- 扩张型心肌病 /
- Meta分析 /
- 疗效
Abstract: Objective: To evaluate the efficacy and safety of stem cell transplantation in patients with dilated cardiomyopathy with meta-analysis.Methods: We searched the randomized controlled trials in PubMed, Embase, and Cochrane library, Medline, Web of Science and CNKI, VIP, WANFANG, CBM until October 2020. The inclusion trials were meta-analyzed by Revman 5.3 and STATA 15. The outcome indexes included mortality and adverse events, left ventricular ejection fraction(LVEF), left ventricular end diastolic chamber size(LVEDCs), left ventricular end systolic chamber size(LVESCs), 6 minutes walking distanse(6 MWD) and NT-proBNP.Results: The 607 patients with dilated cardiomyopathy from 9 trials were involved. The results showed that stem cell therapy wouldn't impove mortality(RR=0.72, 95%CI: 0.52-1.01, P=0.196) neither adverse events(RR=1.25, 95%CI: 0.68-2.27, P=0.617). It could ameliorate LVEF(WMD=5.02, 95%CI: 3.32-6.73, P=0.005), reduces LVEDCs(SMD=-0.82, 95%CI:-1.42--0.22, P=0) and NT-proBNP(WMD=-1534.00, 95%CI:-2410.06--657.95, P=0). However, stem cell therapy has no effect on LVESCs(SMD=0.12, 95%CI:-0.78-1.01, P=0), 6 MWD(WMD=51.39, 95%CI:-11.65-114.43, P=0).Conclusion: This meta analysis suggests that stem cell therapy improves LVEF, reduces LVEDCs and NT-proBNP. However, stem cell therapy has no effect on LVESCs, 6 MWD. And it wouldn't impove mortality neither adverse events. Future well designed large studies might be necessary to clarify the effect of stem cell therapy in patients with dilated cardiomyopathy.
- stem cell transpiantation /
- dilated cardiomyopathy /
- Meta analysis /
- efficacy

HTML全文

参考文献(14)

[1]	Virani SS,Alonso A,Benjamin EJ,et al.Heart disease and stroke statistics-2020 update:a report from the American Heart Association[J].Circ,2020,141(9):e139-e596.
[2]	Murry CE,MacLellan WR.Stem cells and the heart-the road ahead[J].Ence,2020,367(6480):854-855.
[3]	He L,Nguyen NB,Ardehali R,et al.Heart regeneration by endogenous stem cells and cardiomyocyte proliferation:controversy,fallacy,and progress[J].Circ,2020,142(3):275-291.
[4]	Golpanian S,Wolf A,Hatzistergos K E,et al.Rebuilding the damaged heart:mesenchymal stem cells,cell-based therapy,and engineered heart tissue[J].Physiol Rev,2016,96(3):1127-1168.
[5]	Xiao W,Guo S,Gao C,et al.A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy[J].Int Heart J,2017,58(2):238-244.
[6]	Martino H,Brofman P,Greco O,et al.Multicentre,randomized,double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy(the Dilated Cardiomyopathy Arm of the MiHeart Study)[J].Eur Heart J,2015,36(42SI):2898-2904.
[7]	Frljak S,Jaklic M,Zemljic G,et al.CD34(+)Cell transplantation improves right ventricular function in patients with nonischemic dilated cardiomyopathy[J].Stem Cells Transl Med,2018,7(2):168-172.
[8]	Hamshere S,Arnous S,Choudhury T,et al.Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy:the REGENERATE-DCM Clinical Trial[J].Eur Heart J,2015,36(44SI):3061-3069.
[9]	Henry TD,Traverse JH,Hammon BL,et al.Safety and efficacy of ixmyelocel-t an expanded,autologous multi-cellular therapy,in dilated cardiomyopathy[J].Circ Res,2014,115(8):730-740.
[10]	Sant'Anna RT,Fracasso J,Valle FH,et al.Direct intramyocardial transthoracic transplantation of bone marrow mononuclear cells for non-ischemic dilated cardiomyopathy:INTRACELL,a Prospective Randomized Controlled Trial[J].Rev Bras Cir Cardiovasc,2014,29(3):437-447.
[11]	Vrtovec B,Poglajen G,Lezaic L,et al.Effects of intracoronary CD34(+)stem cell transplantation in nonischemic dilated cardiomyopathy patients 5-year followup[J].Circ Res,2013,112(1):165-173.
[12]	Vrtovec B,Poglajen G,Sever M,et al.Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy[J].J Card Fail,2011,17(4):272-281.
[13]	Seth S,Bhargava B,Narang R,et al.The ABCD(Autologous Bone Marrow Cells in Dilated Cardiomyopathy)Trial:A Long-Term Follow-Up Study[J].J Am Coll Cardiol,2010,55(15):1643-1644.
[14]	沈丽娟,陆曙,孔令晶,等.表观遗传学在扩张型心肌病中的研究进展[J].临床心血管病杂志,2021,37(2):100-104.